Budget for a dozen recurring lines, not one, among them the medication, the prescriber visits, the laboratory work, the injection supplies, the shipping, and the specialist oversight. Which of those a health plan touches depends entirely on whether the prescription is an approved somatropin product for a diagnosed deficiency or a compounded secretagogue, because only the first has a billing pathway.
The split that decides your whole budget
Recombinant human growth hormone, generically somatropin, is an approved prescription biologic. DailyMed lists current labels for Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton, and Serostim, along with the longer-acting analogs Skytrofa, Sogroya, and Ngenla. Their labeled uses are narrow: growth failure in children from named causes, and replacement in adults with diagnosed growth hormone deficiency. Serostim sits apart, labeled for HIV-associated wasting.
Everything else marketed under the growth hormone banner is a different financial animal. Sermorelin returns no current DailyMed labels at all, so it exists in the United States only as a compounded preparation. Ipamorelin acetate, GHRP-2, GHRP-6, and ibutamoren mesylate appear on the FDA list of bulk substances that may present significant safety risks in compounding, and CJC-1295 appears there too. Compounded preparations are not FDA-approved and are not reviewed for safety, effectiveness, or quality before they reach a patient.
That distinction is not academic. An approved product has a license number, a national drug code, and a place in formulary logic. A compounded vial has none of those, so no plan has anything to adjudicate.
The compounded side of this market is now shaped by direct-to-consumer telehealth brands, and it helps to know the names before reading any price. Henry Meds, Ro, and Hims and Hers each run a consultation-and-shipment model, and providers such as HealthRX advertise peptide therapy on similar terms. Seeing several operators side by side makes plain that a monthly figure buys a service bundle rather than an approved medicine, which is exactly what the budget table below is built to expose.
The twelve lines to write down
Build the budget as a table of recurring obligations rather than a single monthly figure, because the single figure is almost always the medication line alone.
| Budget line | How often it hits | Approved somatropin path | Compounded path |
|---|---|---|---|
| Initial evaluation | Once | Endocrinology or pediatric endocrinology visit | Telehealth intake, sometimes bundled |
| Diagnostic stimulation testing | Once, sometimes repeated | Required before most coverage decisions | Often skipped entirely |
| Baseline laboratory panel | Once | IGF-I plus pituitary axis screening | Varies by clinic |
| Prior authorization handling | Once, then annually | Clinic staff time, appeal if denied | Not applicable |
| Medication | Monthly or per shipment | Specialty pharmacy fill | Cash payment to the clinic or pharmacy |
| Device or pen | Periodic | Product specific, sometimes separate | Vials and syringes |
| Injection supplies | Monthly | Needles, wipes, sharps disposal | Same, rarely quoted |
| Cold chain shipping | Per shipment | Usually built into the pharmacy fee | Sometimes a separate charge |
| Follow-up prescriber visit | Every one to six months | Dose review against response | Often a subscription line |
| Repeat IGF-I and metabolic labs | Recurring | Standard practice | Frequently excluded |
| Plan cost sharing | Monthly | Specialty tier coinsurance, deductible | None, because nothing is billed |
| Exit costs | Once | Taper decision, final labs | Refund terms, unused inventory |
Why month one lies to you
Month one is unrepresentative in both directions. On the approved side it is usually the most expensive month of the year, because a deductible resets and the diagnostic workup lands at the same time. On the cash side it is often the cheapest, because introductory pricing is common and the first follow-up visit has not happened yet.
A useful budget therefore models month one, month six, and month twelve separately. Month twelve is the honest number, since it includes a renewal visit, repeat labs, and any annual reauthorization the plan requires.
The monitoring line people forget
Growth hormone treatment is titrated against measured response, not against a fixed schedule, and clinical practice guidelines for adult growth hormone deficiency from the Endocrine Society and from the American Association of Clinical Endocrinologists both build around periodic biochemical follow-up and clinician judgment. Testing on a schedule costs money on a schedule.
The same logic applies with more force to compounds that have no approved product behind them. In the two-year randomized trial of an oral ghrelin mimetic in healthy older adults, fasting glucose rose and insulin sensitivity fell, which is exactly the kind of drift that only shows up if somebody orders the panel. A program that never repeats labs is cheaper on paper for the reason that makes it worse.
Where published pricing helps the arithmetic
Cash-pay clinics differ widely in how much they will tell you before an intake form. Some hormone practices, including Defy Medical and Marek Health, have long published service menus; others quote nothing until after a consultation. Among telehealth operators that post cash figures for physician-supervised compounded medication up front, FormBlends is one, and visible pricing at least makes the twelve-line exercise above possible before any money moves.
Visible pricing is not the same as value. A clearly priced monthly charge for a preparation with no approved product and no demonstrated benefit in healthy adults is still a recurring expense against an uncertain return. A systematic review of growth hormone in healthy elderly adults found small body composition changes alongside more frequent swelling, joint pain, and carpal tunnel symptoms, which is a poor trade to fund indefinitely.
Two budget lines that are not financial
Federal law restricts distribution of human growth hormone to uses treating a disease or recognized medical condition authorized by the Secretary of Health and Human Services and ordered by a physician. Anti-aging and athletic use fall outside that. Growth hormone and its secretagogues are also prohibited in sport under the World Anti-Doping Agency code, so a tested athlete is buying a sanction risk alongside the vials.
Neither line has a dollar figure, and both belong in the decision.
Frequently asked questions
What single cost is most often missing from a quoted monthly price?
Repeat laboratory work, with renewal consultation fees close behind. Both recur predictably and both are usually absent from an advertised figure, which normally reflects the medication line only. Asking for the month twelve total rather than the month one total surfaces them immediately.
Does an approved somatropin product cost more than a compounded secretagogue?
The list prices are not comparable in a useful way, because the approved product may be partly covered while the compounded one never is. What matters to a household budget is the amount actually paid after benefits, which can invert the ranking entirely.
Is diagnostic testing worth budgeting for if the plan may deny coverage anyway?
Yes. Stimulation testing is the step that establishes whether a deficiency exists at all, and without it there is no diagnosis to treat, no coverage request to file, and no way to judge whether any later response is meaningful. Skipping it saves the smallest sum in the plan.
Do the weekly products cost less because there are fewer injections?
Fewer injections reduces supply and handling burden, not necessarily spend. Skytrofa, Sogroya, and Ngenla are separately licensed products with their own pricing and their own formulary positions, so the weekly schedule tells you nothing reliable about the monthly total or about how a plan will treat it.
Should an exit cost really be in the budget?
It should. Prepaid blocks, unused inventory, and refund terms differ by provider, and a prescriber can stop a prescription for clinical reasons at any point. Knowing what happens to a balance in that situation is part of knowing what the program costs.
